Literature DB >> 21926053

Psychotropic prescribing in Catalonia: results from an epidemiological study.

Maria Rubio-Valera1, Ana Fernández, Juan V Luciano, Carmel M Hughes, Alejandra Pinto-Meza, Berta Moreno-Küstner, Diego J Palao, Josep Maria Haro, Antoni Serrano-Blanco.   

Abstract

BACKGROUND: Mental disorders (MDs) are mainly treated in primary care (PC), where psychotropic drug (PSD) prescribing is highly prevalent. Prescription of PSD is associated with clinical and non-clinical factors.
PURPOSE: To describe the patterns of PSD prescribing over a 12-month period and to determine the factors associated with this in a PC population.
METHODS: Cross-sectional study. Data were collected on 3815 patients, via patient interview, on sociodemographics and MDs [Diagnostic and Statistical Manual of Mental Disorders (DSM-IV criteria)]. Computerized records provided data on PSD prescribing. Multilevel logistic regressions assessed the factors that influence prescribing.
RESULTS: Thirty-four per cent of PC patients were prescribed PSDs >12 months, with anxiolytics being the most commonly prescribed (22%). Fifty-three per cent of patients with any MD in this 12-month period were prescribed PSDs; however, 25% of patients without any of these disorders were also prescribed these medications. Higher rates of prescribing were associated with female gender, older age, presence of MD, being a househusband/housewife, consulting about psychological problems, increasing number of consultations and higher self-perceived disability. PSDs were less likely to be prescribed to patients born outside Spain and those consulting about physical conditions. PSD prescribing was higher in patients previously married and antipsychotic prescribing was higher in patients never married. No statistically significant associations were found between PSD prescription and education.
CONCLUSIONS: PSD prescribing rates are high in Catalonia and are associated with a number of clinical and non-clinical factors. A significant proportion of patients are receiving these drugs in the absence of MD. These findings need to be considered when prescribing in PC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21926053     DOI: 10.1093/fampra/cmr078

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  8 in total

1.  Cost-effectiveness of antidepressants versus active monitoring for mild-to-moderate major depressive disorder: a multisite non-randomized-controlled trial in primary care (INFAP study).

Authors:  Maria Rubio-Valera; María Teresa Peñarrubia-María; Maria Iglesias-González; Martin Knapp; Paul McCrone; Marta Roig; Ramón Sabes-Figuera; Juan V Luciano; Juan M Mendive; Ana Gabriela Murrugara-Centurión; Jordi Alonso; Antoni Serrano-Blanco
Journal:  Eur J Health Econ       Date:  2019-02-06

2.  Cost-effectiveness of active monitoring versus antidepressants for major depression in primary health care: a 12-month non-randomized controlled trial (INFAP study).

Authors:  Maria Rubio-Valera; Imma Beneitez; María Teresa Peñarrubia-María; Juan V Luciano; Juan M Mendive; Paul McCrone; Martin Knapp; Ramon Sabés-Figuera; Katarzyna Kocyan; Javier García-Campayo; Antoni Serrano-Blanco
Journal:  BMC Psychiatry       Date:  2015-03-31       Impact factor: 3.630

3.  Social differences associated with the use of psychotropic drugs among men and women aged 65 to 74 years living in the community: the International Mobility in Aging Study (IMIAS).

Authors:  Gustave Noufou Nana; Boukaré Doulougou; Fernando Gomez; Alban Ylli; Jack Guralnik; Maria Victoria Zunzunegui
Journal:  BMC Geriatr       Date:  2015-07-20       Impact factor: 3.921

4.  Cost-effectiveness of a community pharmacist intervention in patients with depression: a randomized controlled trial (PRODEFAR Study).

Authors:  Maria Rubio-Valera; Judith Bosmans; Ana Fernández; Maite Peñarrubia-María; Marian March; Pere Travé; Juan A Bellón; Antoni Serrano-Blanco
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

5.  Time Trend in Psychotropic Medication Use in Spain: A Nationwide Population-Based Study.

Authors:  Pilar Carrasco-Garrido; Valentín Hernández-Barrera; Isabel Jiménez-Trujillo; Jesús Esteban-Hernández; Alejandro Álvaro-Meca; Ana López-de Andrés; José Luis DelBarrio-Fernández; Rodrigo Jiménez-García
Journal:  Int J Environ Res Public Health       Date:  2016-11-24       Impact factor: 3.390

6.  Economic evaluation of a guided and unguided internet-based CBT intervention for major depression: Results from a multi-center, three-armed randomized controlled trial conducted in primary care.

Authors:  Pablo Romero-Sanchiz; Raquel Nogueira-Arjona; Antonio García-Ruiz; Juan V Luciano; Javier García Campayo; Margalida Gili; Cristina Botella; Rosa Baños; Adoración Castro; Yolanda López-Del-Hoyo; Mª Ángeles Pérez Ara; Marta Modrego-Alarcón; Fermín Mayoral Cleríes
Journal:  PLoS One       Date:  2017-02-27       Impact factor: 3.240

7.  Gender Differences in the Prevalence of Mental Health, Psychological Distress and Psychotropic Medication Consumption in Spain: A Nationwide Population-Based Study.

Authors:  Clara Maestre-Miquel; Ana López-de-Andrés; Zichen Ji; Javier de Miguel-Diez; Arturo Brocate; Sara Sanz-Rojo; Antonio López-Farre; David Carabantes-Alarcon; Rodrigo Jiménez-García; José J Zamorano-León
Journal:  Int J Environ Res Public Health       Date:  2021-06-11       Impact factor: 3.390

8.  Antidepressants in primary care: patients' experiences, perceptions, self-efficacy beliefs, and nonadherence.

Authors:  Hans Wouters; Marcel L Bouvy; Erica Cg Van Geffen; Helga Gardarsdottir; Anne M Stiggelbout; Liset Van Dijk
Journal:  Patient Prefer Adherence       Date:  2014-02-10       Impact factor: 2.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.